Related Experiment Video
Updated: Aug 7, 2026

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
Published on: November 21, 2025
Reboxetine addition in patients with mirtazapine-resistant depression: a case series
Francisco López-Muñoz1, Gabriel Rubio, Cecilio Alamo
1Department of Pharmacology, Faculty of Medicine, University of Alcalá, Madrid, Spain. frlopez@juste.net
Objectives:
Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, according to Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) criteria, who had previously failed to respond or who had only responded partially, over a period of 6 weeks, to conventional treatment with mirtazapine.
Methods:
Evaluation of antidepressant efficacy was carried out through the application of the 21-item Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impressions-Global Improvement Scale (CGI-I).
Results:
The percentages of responders (HDRS>or=50%), patients in remission (HDRS
Conclusions:
The initial findings of our study show that reboxetine and mirtazapine may constitute an effective and low side effects combination.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Electroconvulsive Therapy
Antidepressant Drugs: Overview
Psychosis: Goals of Pharmacotherapy
G-protein Coupled Receptors

